Sentinel Lymph Node Biopsy in Breast Cancer: Predictors of Axillary and Non-Sentinel Lymph Node Involvement

Logistic stepwise regression analysis disclosed tumour size (odds ratio: 1.51, p=0.0021) andlymphatic vessel invasion (odds ratio: 4.68, p=0.001) as significant primary tumour-related prognostic determinants of SLN metastasis.Conclusion: A close relationship was identified between tumour size and lymphatic vessel invasion of the primary tumour and axillary lymph node involvement.However, the positive predictive value of these two independent variables is low and there is no compelling evidence to recommend their use in routine clinical practice.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Background: Sentinel lymph node biopsy is a standard method for the evaluation of axillary status in patients with T1-2N0M0 breast cancers.Aims: To determine the prognostic significance of primary tumour-related clinico-histopathological factors on axillary and non-sentinel lymph nodeinvolvement of patients who underwent sentinel lymph node biopsy.Study design: Retrospective clinical study.Methods: In the present study, 157 sentinel lymph node biopsies were performed in 151 consecutive patients with early stage breast cancer betweenJune 2008 and December 2011.Results: Successful lymphatic mapping was obtained in 157 of 158 procedures (99.4%).

📊

Key Findings & Data:The incidence of larger tumour size (2.543±1.21 vs. 1.974±1.04),lymphatic vessel invasion (70.6% vs. 29.4%), blood vessel invasion (84.2% vs. 15.8%), and invasive lobular carcinoma subtype (72.7% vs. 27.3%) werestatistically significantly higher in patients with positive SLNs.

💡

Conclusion & Impact:Logistic stepwise regression analysis disclosed tumour size (odds ratio: 1.51, p=0.0021) andlymphatic vessel invasion (odds ratio: 4.68, p=0.001) as significant primary tumour-related prognostic determinants of SLN metastasis.Conclusion: A close relationship was identified between tumour size and lymphatic vessel invasion of the primary tumour and axillary lymph node involvement.However, the positive predictive value of these two independent variables is low and there is no compelling evidence to recommend their use in routine clinical practice.

🔬Design:Research Article

📍Scope:2008 Verileri

⚙️Variables:Domain Parameters

Abstract

Background: Sentinel lymph node biopsy is a standard method for the evaluation of axillary status in patients with T1-2N0M0 breast cancers.Aims: To determine the prognostic significance of primary tumour-related clinico-histopathological factors on axillary and non-sentinel lymph nodeinvolvement of patients who underwent sentinel lymph node biopsy.Study design: Retrospective clinical study.Methods: In the present study, 157 sentinel lymph node biopsies were performed in 151 consecutive patients with early stage breast cancer betweenJune 2008 and December 2011.Results: Successful lymphatic mapping was obtained in 157 of 158 procedures (99.4%). The incidence of larger tumour size (2.543±1.21 vs. 1.974±1.04),lymphatic vessel invasion (70.6% vs. 29.4%), blood vessel invasion (84.2% vs. 15.8%), and invasive lobular carcinoma subtype (72.7% vs. 27.3%) werestatistically significantly higher in patients with positive SLNs. Logistic stepwise regression analysis disclosed tumour size (odds ratio: 1.51, p=0.0021) andlymphatic vessel invasion (odds ratio: 4.68, p=0.001) as significant primary tumour-related prognostic determinants of SLN metastasis.Conclusion: A close relationship was identified between tumour size and lymphatic vessel invasion of the primary tumour and axillary lymph node involvement.However, the positive predictive value of these two independent variables is low and there is no compelling evidence to recommend their use in routine clinical practice.

🔖

Cite This Article

YARARBAŞ, Ü., ELİYATKIN, N., DURUSOY, R., CENGİZ, F., POSTACI, H., AKPINAR, G., ZENGEL, B., USLU, A. (2022). Sentinel Lymph Node Biopsy in Breast Cancer: Predictors of Axillary and Non-Sentinel Lymph Node Involvement. Balkan Medical Journal, Cilt: 30 - Sayı: 4, 415–421. https://ajindex.com/articles/461574

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (2)

Schwartz GF, Giuliano AE, Veronesi U; Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001,
Philadelphia, Pennsylvania. Cancer 2002;94:2542-51. [CrossRef] 2. Dowlatshahi K, Fan M, Snider H, Habib F. Lymph node micrometastases from breast carcinoma:reviewing dilemma. Cancer 1997;80:1188-97. [CrossRef] 3. Colleoni M, Rotmensz Z, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G, et al. Size of breast cancer metastases in axillary lymph nodes:clinical relevance of minimal lymph node involvement. J Clin Oncol 2005;23:1379-89. [CrossRef] 4. van der Heiden-van der Loo M, Schaapveld M, Ho VK, Siesling S, Rutgers EJ, Peeters PH. Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes. Ann Oncol 2013;24:2794-801. [CrossRef] 5. Grabau D, Jensen MB, Rank F, Blichert-Toft M. Axillary lymph node micrometastasis in invasive breast cancer:national figures on incidence and overall survival. APMIS 2007;115:828-37. [CrossRef] 6. Kuijt GP, Voogd AC, van de Poll-Franse LV, Scheijmans LJ, van Beek MW, Roumen RM. The prognostic significance of axillary lymph-node micrometastases in breast cancer patients. Eur J Surg Oncol 2005;31:500-5. [CrossRef] 7. Wada N, Imoto S. Clinical evidence of breast cancer micrometastases in the era of sentinel node biopsy. Int J Clin Oncol 2008;13:24-32. [CrossRef] 8. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426-33. 9. Aitken E, Osman M. Factors affecting nodal status in invasive breast cancer:a retrospective analysis of 623 patients. Breast J 2010;16:271-8. [CrossRef] 10. Wada N, Imoto S, Yamauchi C, Hasebe T, Ochiai A. Predictors of tumour involvement in remaining axillary lymph nodes of breast cancer patients with positive sentinel lymph node. Eur J Surg Oncol 2006;32:29-33. [CrossRef] 11. Alran S, De Rycke Y, Fourchotte V, Charitansky H, Laki F, Falcou MC, et al. Institut Curie Breast Cancer Study Group, Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol 2007;14